Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis

Key facts

Sponsor

Novaliq GmbH

Principal Investigator

Sonja Kroesser, PhD, SLP

Novaliq GmbH

Intervention

Tacrolimus ophthalmic solution(drug)

Enrollment

20 enrolled

Eligibility

18 years · All sexes

Timeline

2026 – 2026

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Anterior uveitis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07552012
  A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIU
  Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
• ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT07218770
  A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants
  Regeneron Pharmaceuticals
• ACTIVE NOT RECRUITINGNANCT07262437
  Targeting Immunosuppressive Treatment for Non-infectious Uveitis Using Aqueous Humor Cytokine Profiles
  University of Milan
• ACTIVE NOT RECRUITINGPHASE3NCT06431373
  A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
  Priovant Therapeutics, Inc.
• RECRUITINGNCT07065747
  Quantification & Classification of Inflammatory Cells in Uveitis Using OCT
  Oregon Health and Science University
• RECRUITINGNCT06720376
  Observational Prospective Turkish Inception Cohort of Uveitis and Spondyloarthritis
  Marmara University
• RECRUITINGPHASE3NCT05486468
  The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
  Texas Retina Associates
• RECRUITINGNANCT05286203
  Ocular Pathogen and Transcriptome Investigation Using Comprehensive Sequencing
  University of California, San Francisco

See all trials for Anterior uveitis →